Oncotarget

Research Papers:

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel

Naoki Fukuda, Daisuke Takahari _, Takeru Wakatsuki, Hiroki Osumi, Izuma Nakayama, Tomohiro Matsushima, Takashi Ichimura, Mariko Ogura, Masato Ozaka, Mitsukuni Suenaga, Eiji Shinozaki, Keisho Chin and Kensei Yamaguchi

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:15219-15227. https://doi.org/10.18632/oncotarget.24635

Metrics: PDF 959 views  |   HTML 1701 views  |   ?  


Abstract

Naoki Fukuda1, Daisuke Takahari1, Takeru Wakatsuki1, Hiroki Osumi1, Izuma Nakayama1, Tomohiro Matsushima1, Takashi Ichimura1, Mariko Ogura1, Masato Ozaka1, Mitsukuni Suenaga1, Eiji Shinozaki1, Keisho Chin1 and Kensei Yamaguchi1

1Department of Gastroenterology, The Cancer Institute Hospital of JFCR, Tokyo, Japan

Correspondence to:

Daisuke Takahari, email: daisuke.takahari@jfcr.or.jp

Keywords: ramucirumab; gastric cancer; hypertension; paclitaxel; toxicity

Received: December 04, 2017     Accepted: February 25, 2018     Epub: March 08, 2018     Published: March 16, 2018

ABSTRACT

Anti-vascular endothelial growth factor (VEGF) therapeutics such as bevacizumab, which are widely used in cancer treatment, commonly leads to hypertension. Moreover, bevacizumab-induced hypertension is associated with improved clinical outcomes in several cancers. We retrospectively analyzed 89 patients with histologically confirmed advanced gastric cancer who received the human monoclonal anti-VEGF receptor-2 antibody ramucirumab plus paclitaxel at our hospital between June 2015 and October 2016 to evaluate the impact of treatment-associated hypertension occurring within the first two treatment cycles (“early hypertension”) on outcome. The objective response rate was 40%, median progression-free survival was 5.4 months, and overall survival was 10.4 months, which is similar to previous reports. Early hypertension in patients who received more than two cycles of ramucirumab + paclitaxel was associated with longer progression-free and overall survival. Objective response rates were also higher in patients with early hypertension. These data indicate that early hypertension may be predictive of better outcomes in gastric cancer patients who receive ramucirumab + paclitaxel treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24635